TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03040401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 1, Ceplene® and Proleukin®
Description: Patients in Cohort 1 will be administered only Ceplene® during the first treatment cycles and Ceplene® in combination with Proleukin® during treatment cycles 2-4.~IL-2 will be administered s.c., 1 µg/kg (=16400 IU/kg) body weight twice daily (BID) during treatment periods. Ceplene® will be administered s.c. 0.5 mg BID after IL-2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 2, Ceplene® and Proleukin®
Description: Patients in Cohort 2 will be administered Ceplene® in combination with Proleukin® during all treatment cycles 1-4.~IL-2 will be administered s.c., 1 µg/kg (=16400 IU/kg) body weight twice daily (BID) during treatment periods. Ceplene® will be administered s.c. 0.5 mg BID after IL-2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 3, Ceplene® and Proleukin®
Description: Cohort 3 will receive either only Ceplene® during treatment cycles 1-4 or Ceplene® in combination with Proleukin® during treatment cycles 1-4. Treatment will be decided by the study committee based on the safety profile of treatment administered to cohort 1 and 2.~IL-2 will be administered s.c., 1 µg/kg (=16400 IU/kg) body weight twice daily (BID) during treatment periods. Ceplene® will be administered s.c. 0.5 mg BID after IL-2.
Study: NCT00826553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Standard of care sedative. Dosage, frequency, and duration will be determined by the managing clinical team.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GABA agonist
Description: Patients sedated with GABA agonists (e.g. propofol, benzodiazepines) during mechanical ventilation will be enrolled. Patients randomized to the GABA agonist arm will continue the sedative that is active at enrollment. The specific drug as well as dosage, frequency, and duration will be determined and titrated by the managing clinical team.
Study: NCT00308945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: travoprost 0.004% (drug)
Description: local drop application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: latanoprost 0.005% (drug)
Description: local drop application
Study: NCT02062138

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: continuous passive motion (CPM)
Description: standard-of-care therapy (control intervention); Patients receive three 30 minutes CPM applications (unilateral op-leg) each day from the second postoperative day until 1 day prior to discharge.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: controlled active motion (CAM I)
Description: Patients receive three 30 minutes CAM applications (unilateral op-leg) each day from the second postoperative day until 1 day prior to discharge.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: controlled active motion (CAM II)
Description: Patients receive three 30 minutes CAM applications (bilateral alternating) each day from the second postoperative day until 1 day prior to discharge.
Study: NCT04887649

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: morphine 3 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: morphine 3 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Description: 4 cc of saline solution in epidural cateter in postpartum

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: morphine 2 mg for epidural cateter in postpartum

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: morphine 2 mg for epidural cateter in postpartum
Study: NCT00747916

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CryoSpray Ablation (TM) System
Description: Subjects will be treated with spray cryotherapy using the CryoSpray Ablation (TM) System at Day 0 using up to 3 cycles of 10-40 second sprays as the studied dosimetry and will cover the affected area, including the tumor and the parietal pleural surface. If disease exists bilaterally, only one side will be sprayed. Subjects will be assessed 2-5 days from the initial treatment (Day 0) to check for mucosal sloughing, to reassess tumor burden and for additional CSA therapy as needed.
Study: NCT00626990

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Prognostic factor analyses

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Prognostic factor analyses

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adjuvant therapy
Description: Patients randomized to adjuvant temozolomide will start adjuvant temozolomide after a 4 week resting period after the end of radiotherapy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adjuvant therapy
Description: Patients randomized to adjuvant temozolomide will start adjuvant temozolomide after a 4 week resting period after the end of radiotherapy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Quality of Life analysis will also be used to assess neurological deterioration free progression

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Quality of Life analysis will also be used to assess neurological deterioration free progression

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Quality of Life analysis will also be used to assess neurological deterioration free progression

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Quality of Life analysis will also be used to assess neurological deterioration free progression

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Radiotherapy will consist of a conventionally fractionated regimen for 6.5 weeks in a once daily schedule

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Radiotherapy will consist of a conventionally fractionated regimen for 6.5 weeks in a once daily schedule

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Radiotherapy will consist of a conventionally fractionated regimen for 6.5 weeks in a once daily schedule

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Radiotherapy will consist of a conventionally fractionated regimen for 6.5 weeks in a once daily schedule
Study: NCT01440998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study: NCT01157845

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BreathID (Methacetin breath test)
Description: 13C-labeled methacetin (75 mg) is given to the patient by mouth in a small volume of water, and expired 13C-labeled carbon dioxide is measured from a nasal cannula.
Study: NCT04245969

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: 448 kilohertz Capacitive Resistive Monopolar Radiofrequency stimulus
Description: 448kilohertz capacitive resistive monopolar radiofrequency will be applied on the shoulder and thoracic area

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham comparator
Description: A simulation of 448kilohertz capacitive resistive monopolar radiofrequency will be carried out to make believe the patient to be treated through this equipment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No intervention
Description: These participants will be assessed at the same time than the rest of participants. They will not receive any kind of treatment.
Study: NCT02669706

Intervention type: DRUG
Intervention: Pentamidine
Description: Pentamidine is an antimicrobial medication given for prevention and treatment of Pneumocystis pneumonia (PJP) caused by Pneumocystis jirovecii
Study: NCT02100124

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reproductive Life Planning (RLP)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reproductive Life Planning (RLP)
Study: NCT01440998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study: NCT02100124

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contraceptive Action Planning

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contraception information

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contraception information

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contraception information
Study: NCT04454359

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multi-nutrient supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01278758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASA404, DMXAA or DXAA
Study: NCT02172027

Intervention type: DEVICE
Intervention: Immunomagnetic Detection
Description: Analysis of pleural effusion through immunomagnetic detection device.
Study: NCT04650737

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: single shot ESBP with dexmedtomidine
Description: Patients in this group will receive errector spine plane block with 30 ml bupivacaine 0.25% plus 1ml of 1µg/kg Dexmedetomidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: continous ESPB
Description: Patients in this group will receive erector spine plane block with 30 ml bupivacaine 0.25%plus 1ml normal salinefollowed by continuous infusion of 8ml / hour of 0.125% bupivacaine for 24 hrs.
Study: NCT01008410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Budesonide will be administered as per the dose and schedule specified in the respective arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to budesonide will be administered as per the schedule specified in the respective arm.
Study: NCT02988050

Intervention type: DRUG
Group type: OTHER
Intervention: Remifentanil
Description: Remifentanil used for conscious sedation.

Intervention type: DRUG
Group type: OTHER
Intervention: Dexmedetomidine
Description: Dexmedetomidine used for conscious sedation.

Intervention type: DRUG
Group type: OTHER
Intervention: Propofol
Description: Used for conscious sedation.

Intervention type: DRUG
Group type: OTHER
Intervention: Propofol
Description: Used for conscious sedation.

Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacaine
Description: Local anaesthetics

Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacaine
Description: Local anaesthetics

Intervention type: DRUG
Group type: OTHER
Intervention: Lidocaine
Description: Local anaesthetic

Intervention type: DRUG
Group type: OTHER
Intervention: Lidocaine
Description: Local anaesthetic

Intervention type: DRUG
Group type: OTHER
Intervention: Epinephrine
Description: With local anaesthetic for skin infiltration.

Intervention type: DRUG
Group type: OTHER
Intervention: Epinephrine
Description: With local anaesthetic for skin infiltration.
Study: NCT02349425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: Gefapixant 7.5 and 50mg tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: Gefapixant 7.5 and 50mg tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: Gefapixant 7.5 and 50mg tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: Gefapixant 7.5 and 50mg tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for gefapixant)
Description: Placebo to gefapixant 7.5 and 50mg tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for gefapixant)
Description: Placebo to gefapixant 7.5 and 50mg tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for gefapixant)
Description: Placebo to gefapixant 7.5 and 50mg tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for gefapixant)
Description: Placebo to gefapixant 7.5 and 50mg tablets administered orally
Study: NCT03022253

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Liberal platelet transfusion
Description: Liberal platelet transfusion: In Intervention group the investigators will transfuse platelet concentrates to maintain a platelet count above 1,00,000 per microliter until one of the following endpoints is met, whichever is applicable:~1. PDA closes or~2. A maximum of 120 hours after the point of randomisation

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Restrictive platelet transfusion
Description: The investigators will transfuse platelets only if:~(i) Platelet count is \< 20,000 per microliter or (ii) Subject has a clinical bleed or (iii) Subject has platelet count \< 50000 per microliter and requires a major non-neurosurgical interventional procedure as per the current standard of care, or (iv) Subject has a platelet count \< 1, 00,000 per microliter and requires a neurosurgical procedure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: As all subjects recruited in the trial will have hemodynamically significant (hs) PDA, they will all be medically treated as per standard of care. Treatment regimens will be as follows, depending on the discretion of the treating physician:~Paracetamol:~Dosage-15 mg/kg/dose every 6 hourly x 12 doses Route - IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: As all subjects recruited in the trial will have hemodynamically significant (hs) PDA, they will all be medically treated as per standard of care. Treatment regimens will be as follows, depending on the discretion of the treating physician:~Paracetamol:~Dosage-15 mg/kg/dose every 6 hourly x 12 doses Route - IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: As all subjects recruited in the trial will have hemodynamically significant (hs) PDA, they will all be medically treated as per standard of care. Treatment regimens will be as follows, depending on the discretion of the treating physician:~Ibuprofen:~Dosage-10 mg/kg stat followed by 5 mg/kg/dose x 2 doses at 24 hours intervals Route- oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: As all subjects recruited in the trial will have hemodynamically significant (hs) PDA, they will all be medically treated as per standard of care. Treatment regimens will be as follows, depending on the discretion of the treating physician:~Ibuprofen:~Dosage-10 mg/kg stat followed by 5 mg/kg/dose x 2 doses at 24 hours intervals Route- oral
Study: NCT04359043

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediational Intervention for Sensitizing Caregivers (MISC)
Description: MISC is an intervention that focuses on increasing the caregiving capacity of the caregiver by enhancing a set of emotional and cognitive components that collectively, sensitizes the caregiver to the emotional and cognitive needs of the child.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as Usual
Description: Treatment as Usual was delivered by community-based organization caseworkers. It consists of a nutritional curriculum of the same dosage and time commitment as the experimental condition, but with no caregiving component.
Study: NCT03205397

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Group
Description: Preparation for anesthesia (explanations, film, booklet), the presence of a parent in the operating room and the awakening of the child

Intervention type: OTHER
Group type: OTHER
Intervention: usual care
Description: Usual care
Study: NCT02154464

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04377685

Intervention type: OTHER
Intervention: CT-Scan
Description: Chest CT scan on admission to the hospital
Study: NCT02124447

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG+E
Description: Split dose 4 liter polyethylene glycol with electrolytes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG+Asc
Description: Split dose 2 liter polyethylene glycol with ascorbic acid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: P+MC
Description: Split dose sodium picosulfate, magnesium oxide, and anhydrous citric acid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sulfate
Description: Split dose sodium sulfate, magnesium sulfate, and potassium sulfate solution
Study: NCT02888210

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MD-15 Intraocular Lens
Study: NCT03017820

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT03101150

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 400 IU Vitamin D3
Description: Antenatal multivitamin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4000 IU Vitamin D3
Description: 4000 IU Vitamin D3 (cholecalciferol) daily = 40 drops daily
Study: NCT01776554

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted H5N1 pandemic influenza vaccine
Description: Comparison of two doses of aH5N1c vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted H5N1 pandemic influenza vaccine
Description: Comparison of two doses of aH5N1c vaccine
Study: NCT03618901

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rock Steady Boxing
Description: Boxing programs as offered by the Rock Steady Boxing institution,

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PD SAFEx
Description: Progressive proprioception training.
Study: NCT03242369

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: colonoscopy
Description: 100 patients undergoing colonoscopy will be prepared with split dose (2+2l) PEG. 2 liters will be drunk during 2 hours in the evening the day before colonoscopy, the second 2l during 2 hours in the day of colonoscopy finishing the dose 4- 6 hours before colonoscopy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: colonoscopy
Description: 100 patients undergoing colonoscopy will by prepared with split dose of SS. The first bottle of SS with water (total volume 0,5l) will be drunk in the evening the day before colonoscopy during 1 hour, than another 1liter of clear fluid will be drunk. The same procedure will be repeated with the second bottle of SS finishing at least 3 hours before colonoscop

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: colonoscopy
Description: 100 patients undergoing colonoscopy will be prepared with split dose of PEG (1+1L) with ascorbic acid. The first 1l of solution will be drunk in the evening the day before colonoscopy, the second 1l of solution in the day of colonoscopy finishing 4-6 hours before the examination. Another 1l of clear fluid should be drunk during the cleansing process.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: colonoscopy
Description: 100 patients undergoing colonoscopy will be prepared with split dose (150ml +150ml) of solution of magnesium acid and sodium picosulfate. The first dose will be drunk in the evening the day before colonoscopy, then at least 1l of another clear fluid will be drunk within a few hours, the second dose will be drunk in the day of examination finishing 4-6hours before colonoscopy and then another at least 750ml clear fluid.
Study: NCT02126280

Intervention type: OTHER
Intervention: In vitro estimation of individual reactivity of monocytes
Description: Technique for isolation/separation of monocytes with culture purity more than 95 % CD14-positive cells according to flow cytometry, the share of viable cells at least 98% by trypan blue vital staining, capable of producing TNFa at concentration of at least 50 pg/ml when stimulated with 100 ng/ml IFN-gamma, and CCL18 at concentration at least 30 pg/ml when stimulated with 10 ng/ml interleukin.

Intervention type: OTHER
Intervention: In vitro estimation of individual reactivity of monocytes
Description: Technique for isolation/separation of monocytes with culture purity more than 95 % CD14-positive cells according to flow cytometry, the share of viable cells at least 98% by trypan blue vital staining, capable of producing TNFa at concentration of at least 50 pg/ml when stimulated with 100 ng/ml IFN-gamma, and CCL18 at concentration at least 30 pg/ml when stimulated with 10 ng/ml interleukin.

Intervention type: OTHER
Intervention: In vitro estimation of individual reactivity of monocytes
Description: Technique for isolation/separation of monocytes with culture purity more than 95 % CD14-positive cells according to flow cytometry, the share of viable cells at least 98% by trypan blue vital staining, capable of producing TNFa at concentration of at least 50 pg/ml when stimulated with 100 ng/ml IFN-gamma, and CCL18 at concentration at least 30 pg/ml when stimulated with 10 ng/ml interleukin.
Study: NCT00563290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03017820

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection